Matt Foehr : Yeah, Puneet. Thanks. This is Matt and then Kurt will probably have some comments here too. Obviously, we’re keep an eye on the space and understand kind of the global landscape. We are coming off a period where there has been a lot of funding into biotech companies, right. So — and I’m speaking kind of in the past here. That we’ve found as we talk to our partners has led to really a focus on investment, I mean, again, coming off a year last year with more new partnerships ever. And there really does seem to be a sustained commitment to discovery, right. I think, on a macro level discovery is obviously important and from a cost perspective with partners we haven’t seen kind of the effects, you’re kind of implying, based on our dialogue with partners.
You go to the conferences, we are at, all they want to talk about is new ways of approaching antibody-based targets, structural elements that our scientists may be the only ones who can elucidate or provide access to. There really is a real focus on remaining at the cutting edge of innovation for that discovery phase. So obviously we continue to watch the landscape etc. But we’re coming off a year where we signed up more new partners than we ever have. That shows a commitment on new partners to want to access the technology to in many instances, quickly ramp up projects. But hopefully, that gives you a little bit of color. Now Kurt, anything you want to add there?
Kurt Gustafson : I mean, I think that’s right. I mean, had you told me a year ago that we would sign more deals in 2022 than ever, I might have questioned that just given the sort of the state of funding in the biotech universe. But clearly, we’re still seeing interest.
Puneet Souda: Right, that’s great and encouraging given the backdrop we’re seeing out there. One other question on maybe for Kurt, on the cash side and position you have and when you look at the capabilities that you have currently on the animal platform, diverse platform across the board, that’s where the strength is. But when you look at the overall technologies hit the stat in terms of screening, identifying the right antibodies down the line, assays and whatnot, given that valuations have sort of come down across the space in some of those technologies, and maybe even to the private markets, how do you think about the overall, your technology stack and capabilities, and investments into that? Should we think about more internal work or organic? Or should we think about more opportunities that you can explore out there to improve that capabilities?
Kurt Gustafson : I think the short answer is both. But I don’t think we need to go do M&A in terms of really, there’s nothing that sort of is missing on the technology stack. That being said, we’ve got — we have our eyes on certain technologies that we think would be synergistic with the technology stack that we have today. And we’re on the lookout for those. And some of that could come through an acquisition of technology that’s external to us today. Some of it will be some internal investment that we’re going to make. But we’ve got an internal strategic plan of how we want to build out our technology stack further. And we’ll execute that. And I think it’ll be a combination of both internal investment as well as some acquired — acquisition of new technology.
Puneet Souda: Got it. And then last one on the OmniChicken platform, you were talking about potential additions to that with cow-inspired ultra long CDRs. So can you just provide update on that, where that stands?